News Aldeyra’s reproxalap for dry eye disease accepted by FDA Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New D
News Aldeyra spies FDA filing ahead for dry eye drug reproxalap Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off.
News Aldeyra builds case for troubled dry eye drug reproxalap Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h
News Iran hackers claim cyberattack at US medtech firm Cyberattack by an Iranian group against Stryker points to a shift in strategy from extortive to destructive assaults, as geopolitical conflicts rise.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
